Zusman T, Gohar O, Eliassi H, Avivi Y, Lisansky E, Sautes C, Even J, Bonnerot C, Fridman W H, Witz I P, Ran M
Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel.
Int J Cancer. 1996 Jan 17;65(2):221-9. doi: 10.1002/(SICI)1097-0215(19960117)65:2<221::AID-IJC16>3.0.CO;2-G.
The murine receptor for the Fc portion of IgG is a molecule expressed by cells of the immune system. This study suggests the hypothesis that Fc gamma receptor type II B I (Fc gamma RIIB I) functions as a progression-enhancing factor when expressed ectopically on non-lymphoid tumor cells. It has been shown previously that BALB/c 3T3 cells transformed in vitro with polyoma virus (PyV) do not express Fc gamma RII but acquire the expression of this receptor following an in vivo passage in syngeneic mice. The specific Fc gamma RII transcript present in tumor cells was identified in this report as Fc gamma RIIB I (BI). In order to determine whether or not the ectopically expressed Fc gamma RII plays a role in the progression of these transformed cells, PyV-transformed 3T3 cells were transfected with BI-cDNA. The BI transfected cells were tested for their ability to form local tumors in syngeneic mice, as compared to transfected cells which express the co-transfecting neomycine resistance (neores) DNA alone or together with the lacZ gene. Fc gamma RIIB I expressors exhibited a significantly higher tumorigenic phenotype than FcR-negative controls, though both types of cells exhibited the same growth curve in vitro. The ability of Fc gamma RIIB I to act as a potentially tumorgenicity-enhancing factor was also demonstrated as Fc gamma RII was expressed by tumor cells, originating from inoculated Fc gamma RIIB I-transfected cells, or from inoculation of a mixture of receptor-positive and -negative cells. B I-expressing cells dominated the tumor-cell population over non-expressors. This dominance strengthened the hypothesis that FcR plays a role in tumor progression in vivo.
IgG Fc段的鼠源受体是一种由免疫系统细胞表达的分子。本研究提出了一个假说,即II B I型Fcγ受体(FcγRIIB I)在非淋巴细胞肿瘤细胞上异位表达时,作为一种促进肿瘤进展的因子发挥作用。先前已有研究表明,用多瘤病毒(PyV)体外转化的BALB/c 3T3细胞不表达FcγRII,但在同基因小鼠体内传代后会获得该受体的表达。本报告中鉴定出肿瘤细胞中存在的特异性FcγRII转录本为FcγRIIB I(BI)。为了确定异位表达的FcγRII是否在这些转化细胞的进展中发挥作用,用BI - cDNA转染PyV转化的3T3细胞。将转染了BI的细胞与单独表达共转染的新霉素抗性(neores)DNA或与lacZ基因一起表达的转染细胞相比,检测其在同基因小鼠体内形成局部肿瘤的能力。FcγRIIB I表达细胞表现出比FcR阴性对照显著更高的致瘤表型,尽管两种类型的细胞在体外具有相同的生长曲线。当肿瘤细胞表达FcγRII时,无论是接种来自FcγRIIB I转染细胞的肿瘤细胞,还是接种受体阳性和阴性细胞的混合物,FcγRIIB I作为潜在的促肿瘤因子的作用也得到了证实。表达BI的细胞在肿瘤细胞群体中比不表达的细胞占优势。这种优势强化了FcR在体内肿瘤进展中起作用的假说。